Sanofi braces for patent cliff impact

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi is girding itself for an ugly year, forecasting a 12%-15%  drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.

Already reeling from patent expirations for Lovenox, Ambien CR and Taxotere in the US and Plavix and Taxotere in the EU, the company will soon be hit with generic competition on Avapro and Eloxatin, which loses US exclusivity in August.

“This is the year we've all had circled in red on our diaries for a number of years now,” said CEO Chris Viehbacher. “We have a number of headwinds facing us.”

Sanofi's diabetes business was a bright spot in 2011, with sales up 12.5% to €1.2 billion in the fourth quarter. Emerging markets sales rose 19% for the quarter compared to the same period a year ago.

Sanofi acquired Genzyme in April, and that part of the company's business, which was reeling from manufacturing problems, is on the mend. Viebacher said the merger is going smoothly and that he sees “a growing sense of confidence and trust among people” at both the firm's ex-Genzyme Boston-area operations and in Europe.

Bernstein analyst Tim Anderson rated the stock “Overperform,” saying “financial performance will be strained because of patent expirations, but consistent revenue and EPS growth seems to return from 2013 onwards, and we feel that as this return-to-growth period draws closer, Sanofi's valuation will expand. What distinguishes Sanofi from many of its peers is that there is a fairly well-defined end to its patent cliff which annualizes in 2013.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...